Data shows surge in in new GLP-1RA prescriptions for obesity without type 2 diabetes
A nationwide study found a marked increase in new GLP-1RA prescriptions over the last decade, particularly since 2020. Semaglutide was the most prescribed GLP-1RA, by far, in 2023. […]